An increasing number of drug injuries are being reported in association with a new anticoagulant medication called Xarelto® (rivaroxaban).
- to reduce the risk of stroke and blood clots in people with atrial fibrillation,
- to treat deep vein thrombosis and pulmonary embolism, and
- reduce the risk of forming a blood clot in the legs and lungs of people who have just had knee or hip replacement surgery.
Xarelto® is manufactured by Janssen Pharmaceuticals© and is marketed as an alternative to warfarin (which has been the most widely prescribed anticoagulant medication for decades). The manufacturer of Xarelto® claims that the medication does not require the same close medical monitoring as warfarin and is therefore easier to use.
However, a May 2014 Report by the Institute for Safe Medication Practices (ISMP) states that in the first quarter of 2013, an increasing number of adverse event reports were filed with the FDA in association with Xarelto®, and that adverse event reports associated with Xarelto® outnumbered adverse event reports of other similar medications. Drug injuries, including bleeding complications associated with blood thinners, can be very serious and even lead to death.